NASDAQ: RADXRadiopharm Theranostics Ltd Stock
$4.06-0.23 (-5.36%)
Updated Jul 2, 2025
RADX Price
$4.06
Fair Value Price
N/A
Market Cap
$26.47M
52 Week Low
$3.50
52 Week High
$50.82
P/E
-0.33x
P/B
0.79x
P/S
31.11x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.06M
Earnings
-$25.37M
Gross Margin
4%
Operating Margin
-2,381.21%
Profit Margin
-2,427.1%
Debt to Equity
0.76
Operating Cash Flow
-$21M
Beta
0.6
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
RADX Overview
Radiopharm Theranostics Limited engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs. It develops RAD 204, a programmed death-ligand 1 (PD-L1) for the treatment of non-small cell lung cancer (NSCLC); RAD 202, a human epidermal growth factor receptor 2 (HER2) to treat breast cancer and other solid tumors; and RAD 301, a diagnostic radiopharmaceutical targeting avß6 integrin in pancreatic ductal adenocarcinoma patients. The company also develops RAD 302, an avß6-integrin targeting agent for the treatment of multiple cancer types; RAD 101 and RAD 102 for brain metastases; RAD 402 to treat advanced prostate cancer; and RV01 for multiple solid tumors. It has strategic agreement with Lantheus Holdings, Inc. to advance the clinical development of radiopharmaceuticals. The company was incorporated in 2021 and is based in Carlton, Australia.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine RADX's potential to beat the market
- RADX doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important RADX news, forecast changes, insider trades & much more!
RADX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how RADX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
RADX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
RADX is good value based on its book value relative to its share price (0.79x), compared to the US Biotechnology industry average (4.52x)
P/B vs Industry Valuation
RADX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more RADX due diligence checks available for Premium users.
Valuation
RADX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.33x
Industry
-134.94x
Market
31.27x
RADX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.79x
Industry
4.52x
RADX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
RADX's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
RADX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
RADX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$57.4M
Liabilities
$25.1M
Debt to equity
0.76
RADX's short-term assets ($27.90M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RADX's short-term assets ($27.90M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RADX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
RADX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
RADX vs Biotech Stocks
Radiopharm Theranostics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.